Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.
Department of Internal Medicine, University of Genoa, Genova, Italy.
Heart Fail Rev. 2022 May;27(3):927-934. doi: 10.1007/s10741-021-10092-y. Epub 2021 Mar 6.
To compare the efficacy and safety of different mechanical circulatory support (MCS) devices in CS. A total of 24 studies (7 randomized controlled trials-RCTs-and 17 non-RCTs) involving 11,117 patients were entered in a Bayesian network meta-analysis. The primary endpoint was 30-day mortality. Secondary endpoints were stroke and bleeding (requiring transfusion and/or intracranial and/or fatal). Compared with no MCS, extra-corporeal membrane oxygenation (ECMO) reduced 30-day mortality when used both alone (OR 0.37, 95% CrI 0.15-0.90) and together with the micro-axial pump Impella (OR 0.13, 95% CrI 0.02-0.80) or intra-aortic balloon pump (IABP) (OR 0.19, 95% CrI 0.05-0.63), although the relevant articles were affected by significant publication bias. Consistent results were obtained in a sensitivity analysis including only studies of CS due to myocardial infarction. After halving the weight of studies with a non-RCT design, only the benefit of ECMO + IABP on 30-day mortality was maintained (OR 0.22, 95% CI 0.057-0.76). The risk of bleeding was increased by TandemHeart (OR 13, 95% CrI 3.50-59), Impella (OR 5, 95% CrI 1.60-18), and IABP (OR 2.2, 95% CrI 1.10-4.4). No significant differences were found across MCS strategies regarding stroke. Although limited by important quality issues, the studies performed so far indicate that ECMO, especially if combined with Impella or IABP, reduces short-term mortality in CS. MCS increases the hazard of bleeding.
比较不同机械循环支持(MCS)设备在 CS 中的疗效和安全性。一项贝叶斯网状荟萃分析纳入了 24 项研究(7 项随机对照试验(RCT)和 17 项非 RCT),共纳入了 11117 例患者。主要终点是 30 天死亡率。次要终点为卒中与出血(需要输血和/或颅内和/或致命性)。与无 MCS 相比,单独使用体外膜肺氧合(ECMO)(OR 0.37,95%CrI 0.15-0.90)以及与微轴流泵 Impella(OR 0.13,95%CrI 0.02-0.80)或主动脉内球囊反搏(IABP)(OR 0.19,95%CrI 0.05-0.63)联合使用时可降低 30 天死亡率,但相关文献受到显著发表偏倚的影响。仅纳入因心肌梗死导致 CS 的研究的敏感性分析中得出了一致的结果。将非 RCT 设计研究的权重减半后,仅 ECMO+IABP 对 30 天死亡率的益处得以维持(OR 0.22,95%CI 0.057-0.76)。TandemHeart(OR 13,95%CrI 3.50-59)、Impella(OR 5,95%CrI 1.60-18)和 IABP(OR 2.2,95%CrI 1.10-4.4)增加了出血风险。不同 MCS 策略在卒中方面未发现显著差异。尽管存在重要的质量问题,但迄今为止开展的研究表明,ECMO 尤其与 Impella 或 IABP 联合使用可降低 CS 的短期死亡率。MCS 增加出血风险。